ABCSG 52 Overview

An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer.

Start: 06/2020
Coordinating Investigator: Greil, Richard (Salzburg), Gnant, Michael (Vienna)
Sample size: 58 (national)
Design:
(Click to enlarge)
Design ABCSG 52 / ATHENE